d6b0ed5e_tus_Filed_Pursuant_to_Rule_424__2
[0] Use of proceeds [2] 
We intend to use the net proceeds from this offering to fund the clinical development of ataluren for the treatment of nmDMD and nmCF, to seek marketing approval in the European Union and the United States for ataluren for these indications, for pre-approval commercial efforts for ataluren, to fund research and development of ataluren for additional indications and for our earlier stage programs, and for working capital and other general corporate purposes.
PTC Therapeutics - Prospectus Filed Pursuant to Rule 424
2